175 related articles for article (PubMed ID: 35924942)
1. Efficacy of the Antimalarial MMV390048 against
Ji S; Galon EM; Rizk MA; Yi Y; Zafar I; Li H; Ma Z; Iguchi A; Asada M; Liu M; Xuan X
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0057422. PubMed ID: 35924942
[TBL] [Abstract][Full Text] [Related]
2. Phosphatidylinositol 4-kinase is a viable target for the radical cure of
Ji S; Galon EM; Amer MM; Zafar I; Yanagawa M; Asada M; Zhou J; Liu M; Xuan X
Front Cell Infect Microbiol; 2022; 12():1048962. PubMed ID: 36452305
[TBL] [Abstract][Full Text] [Related]
3. Could the Drug Tafenoquine Revolutionize Treatment of Babesia microti Infection?
Mordue DG; Wormser GP
J Infect Dis; 2019 Jul; 220(3):442-447. PubMed ID: 31099380
[TBL] [Abstract][Full Text] [Related]
4. Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts.
Tuvshintulga B; Vannier E; Tayebwa DS; Gantuya S; Sivakumar T; Guswanto A; Krause PJ; Yokoyama N; Igarashi I
J Infect Dis; 2020 Aug; 222(6):1027-1036. PubMed ID: 32310272
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of naphthoquine phosphate on Babesia gibsoni in vitro and Babesia rodhaini in vivo.
Ji S; Liu M; Galon EM; Rizk MA; Tuvshintulga B; Li J; Zafar I; Hasegawa Y; Iguchi A; Yokoyama N; Xuan X
Parasit Vectors; 2022 Jan; 15(1):10. PubMed ID: 34991686
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of inhibitory effect of redox-active antimalarial drug against Babesia microti in mice.
Szymczak J; Kozłowska J; Doligalska M
Ann Parasitol; 2017; 63(3):223–227. PubMed ID: 29274217
[TBL] [Abstract][Full Text] [Related]
7. Antimalarial efficacy of MMV390048, an inhibitor of
Paquet T; Le Manach C; Cabrera DG; Younis Y; Henrich PP; Abraham TS; Lee MCS; Basak R; Ghidelli-Disse S; Lafuente-Monasterio MJ; Bantscheff M; Ruecker A; Blagborough AM; Zakutansky SE; Zeeman AM; White KL; Shackleford DM; Mannila J; Morizzi J; Scheurer C; Angulo-Barturen I; Martínez MS; Ferrer S; Sanz LM; Gamo FJ; Reader J; Botha M; Dechering KJ; Sauerwein RW; Tungtaeng A; Vanachayangkul P; Lim CS; Burrows J; Witty MJ; Marsh KC; Bodenreider C; Rochford R; Solapure SM; Jiménez-Díaz MB; Wittlin S; Charman SA; Donini C; Campo B; Birkholtz LM; Hanson KK; Drewes G; Kocken CHM; Delves MJ; Leroy D; Fidock DA; Waterson D; Street LJ; Chibale K
Sci Transl Med; 2017 Apr; 9(387):. PubMed ID: 28446690
[TBL] [Abstract][Full Text] [Related]
8. Macrophages are critical for cross-protective immunity conferred by Babesia microti against Babesia rodhaini infection in mice.
Li Y; Terkawi MA; Nishikawa Y; Aboge GO; Luo Y; Ooka H; Goo YK; Yu L; Cao S; Sun Y; Yamagishi J; Masatani T; Yokoyama N; Igarashi I; Xuan X
Infect Immun; 2012 Jan; 80(1):311-20. PubMed ID: 22064713
[TBL] [Abstract][Full Text] [Related]
9. Tafenoquine Is a Promising Drug Candidate for the Treatment of Babesiosis.
Liu M; Ji S; Kondoh D; Galon EM; Li J; Tomihari M; Yanagawa M; Tagawa M; Adachi M; Asada M; Igarashi I; Iguchi A; Xuan X
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0020421. PubMed ID: 33941516
[TBL] [Abstract][Full Text] [Related]
10. Primary Babesia rodhaini infection followed by recovery confers protective immunity against B. rodhaini reinfection and Babesia microti challenge infection in mice.
Wang G; Efstratiou A; Adjou Moumouni PF; Liu M; Jirapattharasate C; Guo H; Gao Y; Cao S; Zhou M; Suzuki H; Igarashi I; Xuan X
Exp Parasitol; 2016 Oct; 169():6-12. PubMed ID: 27423972
[TBL] [Abstract][Full Text] [Related]
11. A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048.
McCarthy JS; Donini C; Chalon S; Woodford J; Marquart L; Collins KA; Rozenberg FD; Fidock DA; Cherkaoui-Rbati MH; Gobeau N; Möhrle JJ
Clin Infect Dis; 2020 Dec; 71(10):e657-e664. PubMed ID: 32239164
[TBL] [Abstract][Full Text] [Related]
12. Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel
Sinxadi P; Donini C; Johnstone H; Langdon G; Wiesner L; Allen E; Duparc S; Chalon S; McCarthy JS; Lorch U; Chibale K; Möhrle J; Barnes KI
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932368
[TBL] [Abstract][Full Text] [Related]
13. Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection.
Wormser GP; Prasad A; Neuhaus E; Joshi S; Nowakowski J; Nelson J; Mittleman A; Aguero-Rosenfeld M; Topal J; Krause PJ
Clin Infect Dis; 2010 Feb; 50(3):381-6. PubMed ID: 20047477
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects on bovine babesial infection by iron chelator, 1-(N-acetyl-6-aminohexyl)- 3-hydroxy-2-methylpyridin-4-one (CM1), and antimalarial drugs.
Koonyosying P; Srichairatanakool S; Tiwananthagorn S; Sthitmatee N
Vet Parasitol; 2023 Dec; 324():110055. PubMed ID: 37931475
[TBL] [Abstract][Full Text] [Related]
15. Combination of Clofazimine and Atovaquone as a Potent Therapeutic Regimen for the Radical Cure of Babesia microti Infection in Immunocompromised Hosts.
Tuvshintulga B; Sivakumar T; Nugraha AB; Ahedor B; Batmagnai E; Otgonsuren D; Liu M; Xuan X; Igarashi I; Yokoyama N
J Infect Dis; 2022 Jan; 225(2):238-242. PubMed ID: 34664651
[TBL] [Abstract][Full Text] [Related]
16. HIV protease inhibitors block parasite signal peptide peptidases and prevent growth of Babesia microti parasites in erythrocytes.
Schwake C; Baldwin MR; Bachovchin W; Hegde S; Schiemer J; Okure C; Levin AE; Vannier E; Hanada T; Chishti AH
Biochem Biophys Res Commun; 2019 Sep; 517(1):125-131. PubMed ID: 31311649
[TBL] [Abstract][Full Text] [Related]
17. Elimination of
Skariah S; Arnaboldi P; Dattwyler RJ; Sultan AA; Gaylets C; Walwyn O; Mulhall H; Wu X; Dargham SR; Mordue DG
J Immunol; 2017 Jul; 199(2):633-642. PubMed ID: 28607116
[TBL] [Abstract][Full Text] [Related]
18. Impact of Babesia microti infection on the initiation and course of pregnancy in BALB/c mice.
Tołkacz K; Rodo A; Wdowiarska A; Bajer A; Bednarska M
Parasit Vectors; 2021 Mar; 14(1):132. PubMed ID: 33653384
[TBL] [Abstract][Full Text] [Related]
19. Novel diamidines with activity against Babesia divergens in vitro and Babesia microti in vivo.
Nehrbass-Stuedli A; Boykin D; Tidwell RR; Brun R
Antimicrob Agents Chemother; 2011 Jul; 55(7):3439-45. PubMed ID: 21537025
[TBL] [Abstract][Full Text] [Related]
20. Screening for biomarkers reflecting the progression of Babesia microti infection.
Xu B; Liu XF; Cai YC; Huang JL; Zhang RX; Chen JH; Cheng XJ; Zhou X; Xu XN; Zhou Y; Zhang T; Chen SB; Li J; Wu QF; Sun CS; Fu YF; Chen JX; Zhou XN; Hu W
Parasit Vectors; 2018 Jul; 11(1):379. PubMed ID: 29970143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
